{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-002405","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.817055+00:00","generated_at":"2026-06-20T19:39:15.151047+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Seres Therapeutics appoints Claire Fraser, Ph.D. as Class II director and to Audit Committee","bullets":["Board expanded to ten directors; Dr. Fraser appointed as Class II director and to Audit Committee.","Standard non-employee director compensation: $45,000 annual retainer, $10,000 audit committee retainer.","Initial option grant: 48,000 shares at $5.47 exercise price, vesting over four years or upon change in control.","Entered into standard director and officer indemnification agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-002405","json":"https://secwatch.observer/filing/0001193125-23-002405.json","markdown":"https://secwatch.observer/filing/0001193125-23-002405.md","text":"https://secwatch.observer/filing/0001193125-23-002405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523002405/0001193125-23-002405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523002405/d436852d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:39:15.151047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64e6c5fa6f","claim":"Claire Fraser was appointed as Class II Director at Seres Therapeutics, Inc..","evidence_excerpt":"On January 4, 2023, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) increased its size to provide for a total of ten directors authorized to serve on the Board and appointed Claire Fraser, Ph.D. as a Class II director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523002405/0001193125-23-002405-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}